AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates
Synopsis
Aurinia reported adjusted earnings per share of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.
Aurinia Pharmaceuticals Inc. (AUPH) shares gained nearly 4% in Thursday’s pre-market trade after the company posted a fourth-quarter (Q4) earnings and revenue beat.
Aurinia reported adjusted earnings per share (EPS) of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.
However, the company’s 2026 revenue guidance fell short of Wall Street expectations. Aurinia guided for revenue in the range of $315 million and $325 million during the year, but the consensus estimate stood at $326.8 million.
Retail sentiment on Stocktwits around Aurinia Pharmaceuticals trended in the ‘bullish’ territory, with message volumes at ‘high’ levels. The stock was among the top three trending tickers on the platform at the time of writing.
Get updates to this developing story directly on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.